KD Pharma

KD Pharma Group is a CDMO (contract development and manufacturing organisation) offering custom synthesis, lipid and omega-3 purification, small-molecule API and ingredient production, and finished dosage forms such as softgels, liquids and bottling. Its technology portfolio covers extraction, separation, chemical synthesis, encapsulation and packaging. Subsidiary brands listed on the website include KD Nutra, KD Biopharma and KD LabService.

Customers are pharmaceutical companies, which the company serves with APIs, intermediates and custom synthesis, and nutritional supplement companies, which it serves with omega-3 ingredients and finished products. The company operates on a contract manufacturing and development basis. The website also mentions KD Biopharma's work on lipid-based clinical programmes and the OceanBlue nutritional consumer brand.

The company is headquartered in Bexbach, Germany, and its website states it has more than 500 employees worldwide and business units in Europe, the USA and Asia. Its holding company is O3 Holding GmbH. The website announced that Manja Boerman would become CEO effective August 24, 2026. The website lists 13 open positions, mostly in Bexbach, covering production, engineering, procurement, finance, IT and apprenticeships.

Product: Contract development and manufacturing of omega-3 and lipid ingredients, small-molecule APIs and intermediates, and softgel and liquid finished dosage forms.